Enveric Biosciences Inc (ENVB) USD0.01
Enveric Biosciences Inc. (Enveric) is an early-development-stage biosciences company. Enveric focuses on developing evidence-based prescription products and combination therapies containing cannabinoids to address unmet needs in cancer care. It enhances the lives of patients suffering from cancer, by developing palliative and supportive care products for people suffering from side effects of cancer and cancer treatment such as pain or skin irritation. Enveric pipeline product include cannabinoid therapies, Cannabidiol and (CBD) and cannabigerol (CBG) for hard-to-treat cancers, including glioblastoma multiforme (GBM). Cannabinoid is derived from hemp, other botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) used in therapeutic formulations.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.